Overview
flowchart TD
companies_tree_pharmaceutical["Tree Pharmaceutical Co., Ltd."]
companies_tree_pharmaceutical_["Headquarters"]
companies_tree_pharmaceutical -->|"related to"| companies_tree_pharmaceutical_
style companies_tree_pharmaceutical_ fill:#81c784,stroke:#333,color:#000
companies_tree_pharmaceutical_["Osaka"]
companies_tree_pharmaceutical -->|"related to"| companies_tree_pharmaceutical_
style companies_tree_pharmaceutical_ fill:#81c784,stroke:#333,color:#000
companies_tree_pharmaceutical_["Japan"]
companies_tree_pharmaceutical -->|"related to"| companies_tree_pharmaceutical_
style companies_tree_pharmaceutical_ fill:#81c784,stroke:#333,color:#000
companies_tree_pharmaceutical_["Type"]
companies_tree_pharmaceutical -->|"related to"| companies_tree_pharmaceutical_
style companies_tree_pharmaceutical_ fill:#81c784,stroke:#333,color:#000
style companies_tree_pharmaceutical fill:#4fc3f7,stroke:#333,color:#000
Headquarters: Osaka, Japan
Type: Biotechnology Company
Founded: 2015
Focus: Innovative therapeutics for neurological disorders
Tree Pharmaceutical is an Osaka-based biotechnology company dedicated to developing novel therapeutics for neurological and neurodegenerative diseases. The company leverages Japan's world-class academic research to advance innovative drug candidates from discovery through clinical development.
Company Background
...Overview
Mermaid diagram (expand to render)
Headquarters: Osaka, Japan
Type: Biotechnology Company
Founded: 2015
Focus: Innovative therapeutics for neurological disorders
Tree Pharmaceutical is an Osaka-based biotechnology company dedicated to developing novel therapeutics for neurological and neurodegenerative diseases. The company leverages Japan's world-class academic research to advance innovative drug candidates from discovery through clinical development.
Company Background
Tree Pharmaceutical was founded with the mission of translating cutting-edge neuroscience research into effective therapies for patients suffering from devastating neurological diseases. The company focuses on unmet medical needs in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions where current treatment options are limited.
Research and Development Focus
Alzheimer's Disease Program
Tree Pharmaceutical has established a comprehensive Alzheimer's disease research program targeting multiple pathological mechanisms:
TP-001: Amyloid-Targeting Antibody
- Mechanism: Monoclonal antibody targeting [amyloid-beta](/proteins/amyloid-beta) plaques
- Stage: Preclinical development
- Approach: Disease-modifying therapy targeting the core pathology of Alzheimer's disease
The company is developing antibodies that can not only prevent amyloid-beta accumulation but also promote clearance of existing plaques. This approach differentiates Tree's program from purely preventive therapies.
TP-002: [Tau](/proteins/tau) Pathology Modulator
- Mechanism: Small molecule inhibitor of tau phosphorylation and aggregation
- Stage: Lead optimization
- Focus: Targeting neurofibrillary tangles, the second major pathological hallmark of Alzheimer's disease
Parkinson's Disease Program
TP-003: Alpha-Synuclein Aggregation Inhibitor
- Mechanism: Small molecule targeting alpha-synuclein oligomerization
- Stage: Discovery
- Indication: Parkinson's disease with potential extension to Lewy body dementia
Tree Pharmaceutical's Parkinson's program focuses on preventing the toxic oligomerization of alpha-synuclein, which is believed to be the primary driver of dopaminergic neuron loss in Parkinson's disease.
Beyond disease-specific programs, Tree Pharmaceutical is developing a neuroprotection platform with broad applicability:
- Mitochondrial protectors: Compounds that preserve mitochondrial function in stressed [neurons](/entities/neurons)
- Oxidative stress inhibitors: Antioxidant therapies for neuroprotection
- Anti-inflammatory agents: Targeting neuroinflammation as a common pathway in neurodegeneration
Antibody Discovery
Tree Pharmaceutical employs advanced antibody discovery technologies:
- Phage display libraries: For identifying high-affinity antibodies against disease targets
- Humanized antibody platforms: For developing therapeutic antibodies with optimal properties
- Bispecific antibody technology: For targeting multiple pathological mechanisms simultaneously
Small Molecule Chemistry
The company's medicinal chemistry team uses modern approaches:
- Structure-based drug design: Using cryo-EM and X-ray crystallography for target validation
- Computational chemistry: AI-assisted compound design and optimization
- Novel scaffold identification: Exploring chemical space beyond traditional CNS drug-like molecules
Translational Research
Tree Pharmaceutical validates programs using relevant disease models:
- iPSC-derived neurons: Patient-specific models for translational research
- Transgenic mouse models: For in vivo efficacy and pharmacokinetic studies
- Biomarker development: Identifying patient selection biomarkers and treatment response indicators
Academic Partnerships
Tree Pharmaceutical maintains strong collaborations with leading Japanese universities:
Osaka University
The company has a strategic partnership with Osaka University, one of Japan's leading research institutions in neuroscience:
- Joint research programs on Alzheimer's disease mechanisms
- Access to state-of-the-art research facilities
- Talent pipeline for research and development positions
Kyoto University
Collaboration with Kyoto University provides access to:
- Advanced stem cell research capabilities
- Novel drug target identification
- Expertise in protein aggregation mechanisms
Tokyo University of Science
Partnership for natural product-based drug discovery and medicinal chemistry optimization.
Pipeline Overview
| Program | Indication | Mechanism | Development Stage |
|---------|-------------|-----------|-------------------|
| TP-001 | Alzheimer's disease | Amyloid-beta antibody | Preclinical |
| TP-002 | Alzheimer's disease | Tau modulator | Lead optimization |
| TP-003 | Parkinson's disease | Alpha-synuclein inhibitor | Discovery |
| TP-004 | Neuroprotection | Mitochondrial protector | Discovery |
Business Strategy
Development Strategy
Tree Pharmaceutical pursues a phased development approach:
Early-stage development: Advance programs through preclinical validation with academic partners
Clinical proof-of-concept: Partner with larger pharmaceutical companies for clinical development
Global commercialization: Leverage pharmaceutical partnerships for international marketsPartnership Model
The company is actively seeking pharmaceutical partnerships for:
- Co-development agreements: For advancing clinical programs
- Licensing deals: For regional or global commercialization rights
- Acquisition opportunities: For companies seeking to expand their neuroscience pipeline
Funding and Investment
Tree Pharmaceutical has attracted investment from Japanese venture capital firms focused on biotechnology:
- Series A (2016): Initial funding for establishing research operations
- Series B (2019): Funding for pipeline expansion and lead program advancement
- Strategic investment (2022): From pharmaceutical partner for specific program development
Team and Leadership
Tree Pharmaceutical brings together experienced drug developers:
- Scientific founders: Academic researchers from Osaka University with expertise in neurodegenerative disease mechanisms
- Management team: Industry veterans from major Japanese pharmaceutical companies with track records in drug development
- Advisory board: Leading neuroscientists from Japanese and international institutions
Future Outlook
Tree Pharmaceutical aims to become a leading Japanese biotech company in neurology:
Advance lead program to IND: TP-001 targeting Alzheimer's disease
Expand pipeline: Additional programs in Parkinson's disease and rare neurological conditions
Build clinical capabilities: Establish clinical development expertise
International partnerships: Expand beyond Japan for global developmentCross-Linking
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyloid-Beta](/proteins/amyloid-beta-peptide)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Tau Protein](/proteins/tau)
- [Japanese Neurodegeneration Biotech Companies](/companies/japanese-neurodegeneration-biotech)
- [Osaka University](/institutions/osaka-university)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Tree Pharmaceutical corporate information (n.d.)
[Unknown, Alzheimer's Disease Drug Development Pipeline (Alzheimer's & Dementia) (2020)](https://doi.org/10.1016/j.jalz.2020.06.01)
[Unknown, Parkinson's Disease Therapeutics Pipeline (Nature Reviews Drug Discovery) (2021)](https://doi.org/10.1038/nrd.2021.12)